Episode 66 - Beyond Pain Relief: How Hydrogels May Shift the OA Management Paradigm - Jason Lowe

In this episode, Hannah is joined by Dr Jason Lowe, Chief Veterinary Officer at Contura Vet, to explore the use of intra articular hydrogels as a tool in osteoarthritis management, with a specific focus on Arthramid and how this technology may influence synovitis, joint function, pain, and longer term outcomes. Starting with a clear refresher on osteoarthritis pathology, the conversation then moves into how a 2.5% polyacrylamide hydrogel can integrate with synovial tissues and why that might matter clinically. They discuss where the evidence currently sits, what licensing and real world data can and cannot tell us, and why careful case selection remains essential. Practical caveats are emphasised, including the need for appropriate imaging, the realities of sedation or GA for administration, and the importance of rehabilitation to address established physical consequences of OA. The episode closes with broader, big picture OA management takeaways for both vets and caregivers, with actionable tips focused on monitoring, decision making, and building a sustainable plan for the individual dog.

Guest Bio

Dr. Jason Lowe is a respected equine veterinarian and until recently based in Cambridge, New Zealand. With a profound passion for horses and a commitment to their well-being, Dr. Lowe has over 30 years of clinical experience in specialist equine clinics throughout the world. After obtaining his veterinary degree from Massey University, New Zealand, Dr. Lowe embarked on a journey to specialize in equine medicine. He completed a Certificate in Equine Practice from the Royal College, London and a Masters in Business Administration from Waikato University, New Zealand.

Key Takehomes

1. OA is more than cartilage wear and tear. Synovitis and the wider joint environment matter, which is why targeted intra articular approaches are of interest.

2. Hydrogels are not a magic reset. They may support the synovial environment and joint function, but they do not rebuild established biomechanical change on their own. Rehab and time still do the heavy lifting.

3. Evidence is promising but must be interpreted with discipline. Real world and observational data can be useful, but study design, outcome measures, and time horizons influence what you can conclude.

4. Case selection and process are part of the treatment. Imaging, sedation or GA suitability, expectations setting, and a whole dog plan determine whether the option makes sense for that specific patient.

5. OA management remains multi modal. Even if hydrogels help, they sit within a broader strategy including monitoring, weight optimisation, movement plans, pain control where needed, and caregiver education.

Relevant Links

Arthramid (overview): https://arthramid.com/

Arthramid product page (2.5% iPAAG): https://arthramid.com/product/

Contura animal health (veterinary orthopaedics): https://contura.com/animal-health/

Arthrosamid (human equivalent): https://arthrosamid.com/

Contura announcement including Dr Jason Lowe appointment: https://arthramid.com/2024/07/contura-animal-health-holdings-acquires-innovative-medical-solutions/

If you are a caregiver and you are unsure whether pain is part of your dog’s picture, take CAM’s free course Is My Dog in Pain? to learn the common and the subtle signs, and how to gather useful videos and notes for your next vet consult: https://www.cameducation.co.uk/course/is-my-dog-in-pain

Learn more about CAM:

Facebook: https://www.facebook.com/CAMarthritis

Instagram: https://www.instagram.com/canine_arthritis

Youtube: https://www.youtube.com/c/CanineArthritisManagement

LinkedIn: https://www.linkedin.com/company/canine-arthritis-management-ltd

Have questions send them to: [e-mail]

Stay tuned to learn how early detection can make a significant difference in managing OA in younger dogs.